Screener
Kalaris Therapeutics KLRS Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -66.6%— | —— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 12.2×-2.1× | 12.2×+12.1× | 12.9×-73.9× | 12×-43.1× | 14.3×-4.2× | |
| Leverage | ||||||
| Debt-to-equity | 0×— | 0×— | 0×— | —— | —— | |
| Per Share | ||||||
| Book value per share | $2.89-81.7% | $5.16+107% | $2.24+103% | $2.84+107% | $15.76+144% | |
| Valuation | ||||||
| Market capitalization | $97.12M+68.6% | $157.85M— | $108.1M— | $46.57M— | —— | |
| Price / book | 1.4×+0.3× | 2×— | 2.6×— | 0.9×— | —— |
FAQ
- Where do Kalaris Therapeutics's ratios come from?
- Every ratio is computed from Kalaris Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.